Back to top
more

Barinthus Biotherapeutics PLC Sponsored ADR (BRNS)

(Delayed Data from NSDQ)

$1.45 USD

1.45
132,830

+0.03 (1.79%)

Updated Oct 3, 2025 03:57 PM ET

After-Market: $1.38 -0.07 (-4.52%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.81%
2Buy17.98%
3Hold9.90%
4Sell5.43%
5Strong Sell2.74%
S&P50011.32%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value C Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 32% (79 out of 245)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Key Expected Earnings Data

Report Date Period Ending Zacks Consensus Estimate Earnings ESP
11/05/2025

This is an estimated date of earnings release. Neither Zacks Investment Research, Inc. nor its Information Providers can guarantee the accuracy, completeness, timeliness, or correct sequencing of any of the Information on the Web site, including, but not limited to Information originated by Zacks Investment Research, Inc, licensed by Zacks Investment Research, Inc. from Information Providers, or gathered by Zacks Investment Research, Inc. from publicly available sources. There may be delays, omissions, or inaccuracies in the Information.


Time: -- 		9/2025 $-0.45 0.00%

Earnings Summary

For their last quarter, Barinthus Biotherapeutics PLC Sponsored ADR (BRNS) reported earnings of -$0.52 per share, missing the Zacks Consensus Estimate of -$0.29 per share. This reflects a negative earnings surprise of 79.31%. Look out for BRNS's next earnings release expected on November 05, 2025. For the next earning release, we expect the company to report earnings of -$0.45 per share, reflecting a year-over-year decrease of 114.29%.

Earnings History

Research for BRNS

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

*BMO: Before Market Open

*AMC: After Market Close

Price & Consensus

Zacks News for BRNS

BRNS FAQs

Based on past history, Zacks believes Barinthus Biotherapeutics PLC Sponsored ADR (BRNS) will report their next quarter earnings on November 05, 2025. For the next earning release, we expect the company to report earnings of -0.45 per share, reflecting a year-over-year increase of -114.29.

Based on past history, Zacks believes Barinthus Biotherapeutics PLC Sponsored ADR (BRNS) will report their previous quarter earnings %%TIME_OF_DAY_CODE%% on November 05, 2025.

The Zacks Consensus Estimate for Barinthus Biotherapeutics PLC Sponsored ADR (BRNS) for the quarter ending September 2025 is $-0.45 a share. We expect Barinthus Biotherapeutics PLC Sponsored ADR (BRNS) to report earnings in line with the consensus estimate of $-0.45 per share

In the earnings report for the quarter ending in June 2024, Barinthus Biotherapeutics PLC Sponsored ADR (BRNS) announced earnings of $-0.43 per share versus the Zacks Consensus Estimate of $-0.42 per share, representing a surprise of 2.38%.